Overview of Adancor

Property	Description
Active ingredient	Nicorandil (INN)
Form	Oral tablets, Sterile liquid formulation
Pharmacological class	Antianginal drug, Vasodilator
Common use	Prevention and symptomatic relief of chronic stable angina
Origin	Synthetic organic compound

What Type of Medicine is Adancor?

Adancor is the trade name for the active substance Nicorandil (INN), a synthetic organic compound utilized in cardiology as a specialized antianginal drug and vasodilator. Its pharmacological identity is defined by a unique dual mechanism of action, earning it a classification as both a Nitric Oxide (NO) donor and an ATP-sensitive potassium channel opener or (KATP) channel opener. This structural combination provides balanced vasodilation, a differentiating factor that contributes to its clinical recognition as an important second-line therapy for stable angina.

Nicorandil is chemically categorized as a niacinamide derivative. This unique dual composition ensures that the drug is formulated to simultaneously target both the large coronary arteries and the smaller resistance vessels, which is a key distinction from older, single-action vasodilators.

Composition and Available Forms of Nicorandil

The core of the medicine is the single-ingredient product, Nicorandil, which contains a nitrate moiety alongside the component responsible for activating potassium channels. Adancor is a Prescription Only Medicine (POM) in the markets where it is available, underscoring its use in defined patient groups under professional medical supervision.

The high-level dosage forms include oral tablets for maintenance therapy and a sterile liquid formulation for short-term intravenous use in acute settings. This flexibility in preparation ensures the active component can be delivered efficiently via the oral or intravenous routes of administration based on the patient’s clinical need.

General Purpose and Dual-Action Benefit

The primary purpose of Nicorandil is the prevention and symptomatic relief of discomfort related to chronic stable angina pectoris. The drug’s dual-action capability provides a crucial benefit by simultaneously improving blood flow and reducing the heart's workload.

Pharmacological studies confirm that this dual-mode action efficiently addresses the underlying oxygen imbalance, reducing the frequency of angina episodes and improving physical capacity. This means that the medication helps patients sustain activity and reduces the occurrence of chest discomfort. Nicorandil's unique ability to widen both arteries and veins without causing the tolerance often associated with conventional nitrates makes it a recognized strategy for long-term anginal management.

What side effects are possible with Adancor?

Possible Side Effects and Safety Information

The safety profile of Adancor (nicorandil) is documented by governmental regulatory authorities and includes a range of potential adverse reactions, categorized by frequency and system involvement.

Common and Serious Adverse Reactions

Very Common adverse reactions include headache, which is often transient and can diminish with continued treatment.

Common effects typically involve gastrointestinal and nervous system disorders, such as dizziness, nausea, vomiting, and mouth ulceration.

Serious Adverse Reactions focus on the risk of gastrointestinal ulcerations (including in the mouth, skin, and eyes), which can lead to complications like perforation, fistula formation, haemorrhage, and significant weight loss. These ulcers are often difficult to treat and typically require the permanent discontinuation of the medication.

System-Organ Class Involved	Key Adverse Reactions (Common to Very Rare)
Gastrointestinal Disorders	Mouth ulcer, abdominal pain, rectal bleeding, gastrointestinal ulceration, haemorrhage, perforation.
Nervous System Disorders	Headache, dizziness.
Cardiac and Vascular	Hypotension, tachycardia, flushing.
Skin and Eye Disorders	Corneal ulcer, conjunctival ulcer, angioedema.

Safety Restrictions and Monitoring

Adancor is contraindicated in patients with: severe hypotension or shock (including cardiogenic shock); left ventricular dysfunction with low filling pressure or cardiac decompensation; and concurrent use of phosphodiesterase 5 inhibitors (like sildenafil) or soluble guanylate cyclase stimulators due to the risk of a dangerous drop in blood pressure.

Caution is advised when co-administering with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), acetylsalicylic acid (aspirin), or corticosteroids, as this increases the risk of ulcer complications, including bleeding. Due to the potential for dizziness, patients should be cautious when driving or operating machinery until they know how the medicine affects them. The medication is generally not recommended during pregnancy or breastfeeding.

Overdose and Emergency Response

The official regulatory profile for Adancor (Nicorandil) overdose is defined by the severe effects of its vasodilating properties, which primarily affect the cardiovascular system.

Domain	Official Regulatory Statement
Documented Manifestations:	Acute overdosage is associated with exaggerated peripheral vasodilation, a significant fall in blood pressure (hypotension), and a secondary reflex tachycardia (increased heart rate).
Serious Outcomes:	The most severe outcome is profound hypotension, which may progress to a life-threatening state requiring advanced, specialized care.
Antidote Note:	No specific antidote is known for Nicorandil overdose.

Emergency Action Requirements

Official regulatory guidance mandates that immediate medical attention must be sought for any suspected overdosage. Management is centered on comprehensive symptomatic and supportive treatment within a continuous monitoring environment. Required procedural measures include close monitoring of cardiac function and administration of fluid to increase circulating plasma volume (fluid substitution). In situations involving severe or life-threatening hypotension, the official guidance states that the administration of vasopressors must be considered as a critical component of specialized cardiovascular support. These mandated actions emphasize the critical need to counteract the drug’s exaggerated effect and stabilize the patient's hemodynamic status.

Therapeutic Uses of Adancor

Adancor is generally used for the symptomatic treatment of adult patients with stable angina pectoris, a condition where symptoms may intensify temporarily. The medication is commonly applied in contexts where additional symptomatic support is needed to address symptoms related to physical discomfort in the chest.

Relieving Chest Pain and Discomfort in Stable Angina

Adancor may be part of symptomatic management to help reduce the occurrence of the recurring chest pain and pressure known as stable angina pectoris. The medication is applied in addressing symptoms related to physical discomfort, and may assist with managing the intensity and frequency of these manifestations.

Improving Comfort and Functional Support

This medicine is used for managing symptoms that interfere with daily comfort. It contributes to supporting the patient during episodes of heightened discomfort and assists with supporting general well-being during symptomatic phases. It is relevant in clinical settings where additional support for symptom management is appropriate as part of the long-term strategy for stable angina. It is commonly used when symptoms require additional symptomatic support, providing support that helps ease the overall symptom burden.

Quick Fact: Relief for Recurring Chest Discomfort

Regulatory References

European Commission Community Register

Eligibility and Restrictions for Use

Adancor (Nicorandil) is approved for use exclusively in adults as a second-line treatment for stable angina pectoris. Its eligibility profile is strictly defined by regulatory contraindications and population restrictions found in official labeling.

Contraindicated Populations

Use is strictly prohibited in patients with:

Shock (including cardiogenic shock) or severe hypotension.
Left ventricular dysfunction with low filling pressure, hypovolaemia, or acute pulmonary oedema.
Concomitant use with Phosphodiesterase 5 (PDE5) inhibitors (e.g., sildenafil) or soluble guanylate cyclase (sGC) stimulators.
Known hypersensitivity to nicorandil or any component of the product.

Restricted and Non-Recommended Use

Population	Regulatory Status
Paediatric Population	Not recommended; safety and efficacy are not established.
Pregnant Women	Not recommended; use should be avoided unless considered essential.
Breastfeeding Women	Not recommended; unknown if excreted in human milk.
Elderly Patients	Permitted with care; no special dose requirement, but the lowest effective dose is recommended.
Comorbidities	Caution is advised for patients with NYHA Class III or IV heart failure, G6PD deficiency, or diverticular disease. Treatment must be discontinued if GI ulceration occurs.

Official regulatory documents define these clear exclusions and conditional restrictions, limiting the use of Adancor to specific patient groups where its eligibility has been formally documented.

What should I know about interactions with other medicines?

Adancor’s official interaction profile is defined by combinations that are formally restricted due to specific regulatory concerns. Co-administration with Phosphodiesterase 5 (PDE5) Inhibitors (e.g., sildenafil, tadalafil) and Soluble Guanylate Cyclase (sGC) Stimulators (e.g., riociguat) is strictly contraindicated. This prohibition is enforced due to the synergistic pharmacodynamic effect leading to a serious, precipitous fall in systemic blood pressure.

The blood pressure-lowering effect of Nicorandil may be increased by concurrent use with other antihypertensive agents and other medicinal products with known hypotensive effects, including tricyclic antidepressants and alcohol.

Regulatory documentation also highlights an increased risk for severe complications. Concomitant use with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including acetylsalicylic acid, increases the documented risk for severe gastrointestinal complications such as ulceration, perforation, and hemorrhage. Caution is also advised when co-administering with corticosteroids due to reported gastrointestinal perforations.

Furthermore, Nicorandil requires caution when used with products that may increase potassium levels, especially in the presence of moderate to severe renal impairment, due to the potential for severe hyperkalaemia. Nicorandil's clearance is documented as not being significantly affected by the co-administration of the common metabolic pathway modifiers cimetidine or rifampicin.

Mechanism of Action

How Adancor Works

Nicorandil (Adancor) exerts a dual mechanism of action that modulates vascular tone by engaging two distinct molecular pathways. First, the molecule acts as an agonist by binding to ATP-sensitive potassium (K ATP ) channels found on vascular smooth muscle cells. This interaction facilitates potassium ion efflux, leading to cell hyperpolarization and subsequent restriction of calcium ion influx. This K ATP action primarily causes the relaxation of arterioles (resistance arteries), resulting in the physiological consequence of reducing the heart's afterload.

Simultaneously, a nitrate moiety within Nicorandil releases Nitric Oxide (NO), a gaseous signaling molecule. The NO activates soluble Guanylate Cyclase ( sGC) inside the cell, increasing the second messenger cGMP, which promotes smooth muscle relaxation. This action predominantly dilates large arteries and veins, producing the physiological consequence of reducing the heart's preload and increasing coronary blood flow. The coordinated activity of these two molecular pathways exerts a balanced vasodilatory effect, resulting in modulated oxygen delivery parameters and a reduction of cardiac load parameters.

Dosage and Administration Information

Instruction Map: How to use Adancor — Official Administration Guidelines

Administration scope
Route of administration:	Oral administration only.
Dosing schedule:	Starting Dose: 10 mg twice daily (bid). A lower dose of 5 mg bid may be initiated for patients prone to headache. Therapeutic Range: 10 mg to 20 mg bid. The dose may be titrated upwards, if necessary, up to a maximum of 40 mg bid.
Timing in relation to meals (if applicable):	Administration is independent of food intake.
Preparation requirements (if applicable):	Tablets must be swallowed whole with liquid and should not be crushed or chewed. Tablets are scored and can be divided into equal doses.
Age-group administration rules:	Older Adults: Use of the lowest effective dose is recommended, with no special requirement for dose reduction. Pediatric Population (<18 years): Use is not recommended due to insufficient data.
Missed-dose rules:	If a dose is forgotten, the next dose should be taken at the scheduled time; do not take a double dose to compensate.
Special procedural conditions:	Tablets must be kept in their original blister pack until intake due to moisture sensitivity.

Instruction classifications (high-level)
Administration method type:	Oral (Tablet).
Frequency pattern:	Twice daily (bid), preferably morning and evening.
Use-context constraints:	Intended for long-term treatment; dosage requires titration based on patient response and tolerance.

Resulting Procedural Structure

Official step sequence:

Initiate treatment at the starting dose of 10 mg twice daily, with a 5 mg dose used for susceptible patients.
Swallow the tablet whole with liquid, taking it directly from the blister pack in the morning and evening, independent of food.
Adjust the dosage upward according to individual tolerance, remaining within the official maximum limits for long-term maintenance.

Connection to the overall use protocol (2–4 sentences): The official instructions establish Adancor as a continuous, twice-daily oral therapy that requires an initial adjustment phase to determine the specific maintenance dose for long-term use. This approach dictates the precise method of intake, the exact frequency pattern, and sets boundaries for the maximum dose, ensuring standardized usage.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Chronic Pain Management Studies

Studies have evaluated the use of this drug in managing moderate to severe chronic pain. Research has established that the drug’s activity relates to inhibiting the reuptake of both serotonin and norepinephrine.

Clinical trials investigated changes in patient-reported pain scores. Furthermore, studies explored whether the drug's use related to reports of pain interference with daily activities, and examined changes in overall symptom burden.

The combination of actions was evaluated in most adult patient populations who met inclusion criteria for the studies.

Key Findings from Phase 3 Trials

A Phase 3 multicenter study explored pain relief scores and noted variations when comparing the drug to a placebo group. Secondary endpoints included data on associated symptoms like insomnia and anxiety.

Dosage levels in the trials varied, and the data informed the need for continued investigation into therapeutic benefit.

Safety and Tolerability Profile

Discontinuation of the drug has been explored in studies in relation to reported withdrawal symptoms. The most commonly reported adverse events during trials included nausea, dry mouth, and fatigue. These events were typically reported as mild to moderate and trial observations documented their course in participants.

Research continues to explore potential long-term outcomes, including the possible relationship between the drug’s use and the risk of chronic disability. The formulation was designed to explore its impact on patient compliance.

Key Studies & References A Look at Commonly Utilized Serotonin Noradrenaline Reuptake Inhibitors (SNRIs) in Chronic Pain (Mechanism and Efficacy)

Frequently Asked Questions (FAQ)

Common questions about Adancor (FAQ)

Q: Is Adancor a type of beta-blocker or a nitrate?

Adancor's active substance, nicorandil, has a dual mechanism of action. Official information states it acts as both a Nitric Oxide (NO) donor and an ATP-sensitive potassium channel opener. While one component is similar to nitrates, it is a unique type of medicine and is not classified as a beta-blocker.

Q: Why is Adancor sometimes prescribed when other heart medicines haven't worked?

Regulatory guidance defines Adancor as a second-line treatment for chronic stable angina. This means it is typically considered for adult patients who have not responded adequately to standard initial therapies, such as beta-blockers or calcium antagonists, or who cannot tolerate those other medicines.

Q: Why are headaches a very common side effect when starting Adancor?

Headaches are documented as a very common side effect. This is believed to be related to the drug's effect of causing vasodilation, which is the widening of blood vessels. This vasodilation is the essential action that helps the heart, but it can also trigger headaches.

Q: What are the serious, but rare, side effects mentioned for Adancor?

Serious adverse reactions that have been reported include gastrointestinal ulcerations (such as mouth, skin, and eye ulcers) which can lead to severe complications like bleeding, perforation, or the formation of a fistula (an abnormal connection between organs or vessels).

Q: What kind of painkillers are unsafe to take with Adancor?

Regulatory documents state that co-administration with classes of medicine like Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and corticosteroids increases the documented risk for severe gastrointestinal problems like ulceration and bleeding. This is due to a heightened risk of complications when these medicines are used together.

Q: Is it necessary to avoid alcohol completely while using Adancor?

Regulatory documents state that consuming alcohol may increase the blood pressure-lowering effect (hypotensive effect) of Adancor. Because of this potential for a drop in blood pressure, some official consumer information suggests that alcohol should be avoided while using this medicine.

Q: Are there any special considerations for older adults taking Adancor?

Official guidance permits the use of Adancor in older adults with care. While there is no special requirement for dose reduction based solely on age, regulatory guidance specifies that the lowest effective dose is recommended for use in this population.

Q: How quickly should I expect Adancor to start working?

Studies summarizing the drug's action suggest that Adancor starts to work in the body approximately one hour after the tablet is taken. However, it may take about four to five days of continuous use to realize the full therapeutic effect.

Q: Is Adancor meant to be taken for a short time or long-term?

Adancor is formally indicated for the long-term treatment and prevention of chronic stable angina pectoris. It is designed to be a continuous oral therapy.

Q: Will Adancor cause me to feel dizzy or light-headed?

Official safety information lists dizziness as a common adverse reaction. Due to the potential for the medicine to lower blood pressure, some consumer materials also mention feeling light-headed as a possibility.

Q: Do the headaches from Adancor usually go away over time?

Clinical trial summaries indicate that the headaches are often transient. They tend to be most frequent at the beginning of treatment but are documented to improve or resolve with continued, regular use.

Q: Is it normal to feel more tired than usual when taking Adancor?

Official documents listing potential adverse effects have included reports of tiredness and drowsiness.

Q: Does Adancor cause mouth ulcers or other gastrointestinal problems?

Official safety documentation lists mouth ulceration as a common side effect. Other reported gastrointestinal issues include nausea, vomiting, abdominal pain, and, less commonly, severe gastrointestinal ulcerations.

Q: What is the risk of skin ulcers, such as peri-anal ulcers, while taking Adancor?

Official regulatory documents report the risk of skin and mucosal ulcerations, in addition to gastrointestinal ulcers. While the specific term 'peri-anal' is not universally used, this type of ulcer falls within the scope of mucosal and skin ulcerations that have been reported with the drug.

Q: Can Adancor affect my blood pressure too much?

Adancor is a vasodilator, meaning it can lower blood pressure. It is strictly contraindicated in patients with severe hypotension (very low blood pressure) or shock. The combination with certain other blood pressure-lowering drugs is prohibited due to the risk of a dangerous and precipitous fall in pressure.

Q: Does Adancor affect a person's weight (cause weight gain or loss)?

Official reports of adverse effects have included reports of both loss of appetite and weight loss.

Q: Is there evidence that Adancor offers cardioprotective effects?

Scientific literature related to the drug's pharmacology, specifically its action as an ATP-sensitive potassium channel-agonist, suggests that it may exert a direct cytoprotective effect on the heart muscle against damage related to ischemic events.

Q: What does 'KATP channel opener' mean, in simple terms related to Adancor?

The term KATP channel opener describes a key way Adancor works. It means the medicine activates molecular gateways (potassium channels) in blood vessel cells, allowing potassium ions to leave. This process causes the smooth muscle cells to relax, which leads to the widening of arteries.

Q: How does Adancor help the heart by reducing 'preload' and 'afterload'?

Adancor is known to produce balanced vasodilation. Official documents explain that its dual action reduces both ventricular preload (the amount of blood returning to the heart) and afterload (the resistance the heart pumps against). This reduction in cardiac workload helps improve blood flow and oxygen supply to the heart.

Q: What happens to the body when Adancor causes blood vessel dilation?

When Adancor causes blood vessel dilation (widening), two key things happen. It increases the blood and oxygen supply to the heart muscle, and simultaneously reduces the work the heart needs to do to circulate blood throughout the body.

Q: Can Adancor be used to treat a sudden, acute episode of chest pain?

The oral tablet formulation of Adancor is formally indicated for the prevention and long-term management of chronic stable angina pectoris. It is not approved for the immediate or acute relief of a sudden episode of chest pain.

Q: Does Adancor lose effectiveness (tolerance) over time?

Clinical summaries state that, unlike some older nitrate-based medications, the development of tolerance—where the drug becomes less effective over time—does not appear to be a problem with Adancor.

Q: Can Adancor be taken with other heart rhythm medications?

Official safety documents report that no pharmacological or pharmacokinetic interaction has been observed when Adancor is co-administered with beta-blockers or calcium antagonists, which are classes of medications commonly used for heart rhythm.

Q: Can Adancor cause a feeling of a fast or irregular heartbeat (palpitations)?

Official safety information lists tachycardia (a fast heartbeat) as a potential side effect.

Q: Why is Adancor sometimes given a lower starting dose (e.g., 5mg)?

Regulatory documents indicate that a lower starting dose of 5 mg twice daily may be used specifically for patients who are susceptible to, or prone to experiencing, headache, which is a common initial side effect.

Q: Does Adancor interact with medicines for depression or anxiety?

The blood pressure-lowering effect of Adancor may be increased when it is used alongside other medicinal products with known hypotensive effects, which includes a class of medications called tricyclic antidepressants.

Q: What are the guidelines regarding driving or operating machinery while on Adancor?

Due to the potential for side effects like dizziness or light-headedness, official consumer guidelines advise patients to be cautious when driving or operating machinery. Patients are advised to understand how the medicine affects them before engaging in these activities.

How should Adancor be stored and disposed of?

How to Store and Dispose of Adancor?

Adancor (nicorandil) tablets require specific conditions for storage and handling to ensure product stability, as detailed in regulatory labeling.

Storage Requirements

Adancor must be stored at a temperature not exceeding 25^circC and protected from moisture. The medicine should be kept in the original package, and tablets must remain in their blister until intake due to moisture sensitivity. Once a blister strip is opened, it must be used within 30 days. As with all medicines, Adancor must be kept out of the sight and reach of children.

Disposal Instructions

Expired or unused Adancor must be disposed of in accordance with local requirements. It should not be thrown away via household waste or wastewater. A pharmacist can provide guidance on proper disposal procedures.

Adancor